Common genetic polymorphisms of adenosine A2A receptor do not influence response to regadenoson. (April 2017)

• Record Type: Journal Article
• Authors: Berlacher, Mark; Mastouri, Ronald; Philips, Santosh; Skaar, Todd C; Kreutz, Rolf P
• Is Part Of: Pharmacogenomics. Volume 18:Number 6(2017)
• Page Start: 523
• Page End: 529
• Publication Date: 2017-04
• Subjects: adenosine -- genetic -- myocardial perfusion imaging -- regadenoson; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0178
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Hemodynamic response to regadenoson varies greatly, and underlying mechanisms for variability are poorly understood. We hypothesized that five common variants of adenosine A2A receptor (ADORA2A) are associated with altered response to regadenoson.Methods: Consecutive subjects (n = 357) undergoing resting regadenoson nuclear stress imaging were enrolled. Genotyping was performed using Taqman-based assays for rs5751862, rs2298383, rs3761422, rs2267076 and rs5751876.Results: There was no significant difference in heart rate or blood pressure between different genotypes following regadenoson administration. There was also no significant difference in myocardial ischemia detected by nuclear perfusion imaging as defined by summed difference score, or in self-reported side effects among the genotypes tested.Conclusion: The common A2A variants studied are not associated with variability in hemodynamic response to regadenoson or variability in detection of ischemia with nuclear perfusion stress imaging.